[
  {
    "title": "艾力斯(688578.SH)：近日收到政府补助款项600万元",
    "href": "http://stock.jrj.com.cn/2022/12/26154237238032.shtml",
    "datetime": "2022-12-26 15:42:14",
    "code": "688578"
  },
  {
    "title": "艾力斯(688578.SH)：拟使用不超10亿元暂时闲置募集资金进行现金管理",
    "href": "http://stock.jrj.com.cn/2022/12/14154537211922.shtml",
    "datetime": "2022-12-14 15:45:06",
    "code": "688578"
  },
  {
    "title": "艾力斯(688578.SH)：270万股战略配售股将于12月2日解禁",
    "href": "http://stock.jrj.com.cn/2022/11/24171137164090.shtml",
    "datetime": "2022-11-24 17:11:16",
    "code": "688578"
  },
  {
    "title": "艾力斯：因自身资金需求 股东唐玉投资拟减持不超2%公司股份",
    "href": "http://stock.jrj.com.cn/2022/11/15193737141451.shtml",
    "datetime": "2022-11-15 19:37:57",
    "code": "688578"
  },
  {
    "title": "艾力斯：唐玉投资拟减持公司不超2%股份",
    "href": "http://stock.jrj.com.cn/2022/11/15155737140290.shtml",
    "datetime": "2022-11-15 15:57:54",
    "code": "688578"
  },
  {
    "title": "艾力斯：唐玉投资拟减持不超2%公司股份",
    "href": "http://stock.jrj.com.cn/2022/11/15155037140279.shtml",
    "datetime": "2022-11-15 15:50:25",
    "code": "688578"
  },
  {
    "title": "艾力斯(688578.SH)：唐玉投资拟减持不超2%股份",
    "href": "http://stock.jrj.com.cn/2022/11/15154837140266.shtml",
    "datetime": "2022-11-15 15:48:38",
    "code": "688578"
  },
  {
    "title": "艾力斯(688578.SH)：第三季度净利降87.26%至2716.78万元",
    "href": "http://stock.jrj.com.cn/2022/10/28182037094753.shtml",
    "datetime": "2022-10-28 18:20:58",
    "code": "688578"
  },
  {
    "title": "艾力斯(688578.SH)：1500万股限售股将于10月24日解禁",
    "href": "http://stock.jrj.com.cn/2022/10/14155537056126.shtml",
    "datetime": "2022-10-14 15:55:25",
    "code": "688578"
  },
  {
    "title": "艾力斯(688578.SH)：聘任杜锦豪为总经理",
    "href": "http://stock.jrj.com.cn/2022/09/14154836994068.shtml",
    "datetime": "2022-09-14 15:48:08",
    "code": "688578"
  },
  {
    "title": "扭亏为盈 艾力斯2022年半年度净利润2676.45万元",
    "href": "http://stock.jrj.com.cn/2022/08/26092136939168.shtml",
    "datetime": "2022-08-26 09:21:23",
    "code": "688578"
  },
  {
    "title": "艾力斯(688578.SH)：甲磺酸伏美替尼片20外显子插入突变NSCLC适应证获批临床试验",
    "href": "http://stock.jrj.com.cn/2022/08/19174836916860.shtml",
    "datetime": "2022-08-19 17:48:01",
    "code": "688578"
  },
  {
    "title": "艾力斯（688578）：于-举行投资者关系活动",
    "href": "http://stock.jrj.com.cn/2022/08/08091836877655.shtml",
    "datetime": "2022-08-08 09:18:19",
    "code": "688578"
  },
  {
    "title": "艾力斯(688578.SH)：甲磺酸伏美替尼片一线治疗适应证药品注册申请已处于“审批完毕-待制证”阶段",
    "href": "http://stock.jrj.com.cn/2022/06/29153936767778.shtml",
    "datetime": "2022-06-29 15:39:54",
    "code": "688578"
  },
  {
    "title": "艾力斯2022年第一季度亏损2267.34万同比亏损减少 伏美替尼境内产品销售收入增长",
    "href": "http://stock.jrj.com.cn/2022/05/04123236555281.shtml",
    "datetime": "2022-05-04 12:32:40",
    "code": "688578"
  },
  {
    "title": "艾力斯2021年净利1827.46万同比扭亏为盈 董事长杜锦豪薪酬187.5万",
    "href": "http://stock.jrj.com.cn/2022/04/27221036486888.shtml",
    "datetime": "2022-04-27 22:10:07",
    "code": "688578"
  },
  {
    "title": "扭亏为盈 艾力斯2021年全年净利润1827.46万元",
    "href": "http://stock.jrj.com.cn/2022/04/27091636481305.shtml",
    "datetime": "2022-04-27 09:16:51",
    "code": "688578"
  },
  {
    "title": "艾力斯2021年净利1827.46万同比扭亏为盈 销售数量环比上升",
    "href": "http://stock.jrj.com.cn/2022/02/26051234474347.shtml",
    "datetime": "2022-02-26 05:12:40",
    "code": "688578"
  },
  {
    "title": "艾力斯2021年预计净利1698万-2031万同比扭亏为盈 国内市场销售增长",
    "href": "http://stock.jrj.com.cn/2022/01/27193134231734.shtml",
    "datetime": "2022-01-27 19:31:47",
    "code": "688578"
  },
  {
    "title": "艾力斯(688578.SH)2021年度预盈1698万到2031万元 同比扭亏为盈",
    "href": "http://stock.jrj.com.cn/2022/01/27175834231233.shtml",
    "datetime": "2022-01-27 17:58:28",
    "code": "688578"
  },
  {
    "title": "艾力斯浦东违法被罚20万 未取得许可发布处方药广告",
    "href": "http://stock.jrj.com.cn/2021/12/17142634025936.shtml",
    "datetime": "2021-12-17 14:26:00",
    "code": "688578"
  },
  {
    "title": "艾力斯(688578.SH)：拟使用不超14亿元闲置募集资金进行现金管理",
    "href": "http://stock.jrj.com.cn/2021/12/14161934014571.shtml",
    "datetime": "2021-12-14 16:19:43",
    "code": "688578"
  },
  {
    "title": "艾力斯(688578.SH)：甲磺酸伏美替尼片新纳入国家医保目录",
    "href": "http://stock.jrj.com.cn/2021/12/03155833960177.shtml",
    "datetime": "2021-12-03 15:58:40",
    "code": "688578"
  },
  {
    "title": "艾力斯：甲磺酸伏美替尼片新纳入国家医保目录",
    "href": "http://stock.jrj.com.cn/2021/12/03155533960165.shtml",
    "datetime": "2021-12-03 15:55:32",
    "code": "688578"
  },
  {
    "title": "艾力斯(688578.SH)：1.17亿股限售股将于12月2日解禁上市",
    "href": "http://stock.jrj.com.cn/2021/11/24162833914433.shtml",
    "datetime": "2021-11-24 16:28:39",
    "code": "688578"
  },
  {
    "title": "A股异动 | 艾力斯(688578.SH)涨4.5% 核心产品纳入拟突破性治疗品种公示名单",
    "href": "http://stock.jrj.com.cn/2021/11/24094533913144.shtml",
    "datetime": "2021-11-24 09:45:12",
    "code": "688578"
  },
  {
    "title": "艾力斯(688578.SH)：甲磺酸伏美替尼片纳入拟突破性治疗品种公示",
    "href": "http://stock.jrj.com.cn/2021/11/23175933910224.shtml",
    "datetime": "2021-11-23 17:59:28",
    "code": "688578"
  },
  {
    "title": "扭亏为盈 艾力斯2021年前三季度净利润1.35亿元",
    "href": "http://stock.jrj.com.cn/2021/10/31215233785436.shtml",
    "datetime": "2021-10-31 21:52:44",
    "code": "688578"
  },
  {
    "title": "艾力斯(688578.SH)第三季度净利润2.13亿元",
    "href": "http://stock.jrj.com.cn/2021/10/29204033779791.shtml",
    "datetime": "2021-10-29 20:40:21",
    "code": "688578"
  },
  {
    "title": "继续亏损！艾力斯今年上半年净亏损7834.18万元",
    "href": "http://stock.jrj.com.cn/2021/08/24173933310749.shtml",
    "datetime": "2021-08-24 17:39:22",
    "code": "688578"
  },
  {
    "title": "艾力斯2021年半年度亏损7834.18万元 同比亏损减少",
    "href": "http://stock.jrj.com.cn/2021/08/24165033310492.shtml",
    "datetime": "2021-08-24 16:50:52",
    "code": "688578"
  },
  {
    "title": "艾力斯(688578.SH)：上半年净亏损7834.18万元",
    "href": "http://stock.jrj.com.cn/2021/08/24163233310303.shtml",
    "datetime": "2021-08-24 16:32:20",
    "code": "688578"
  },
  {
    "title": "为拓展核心产品海外市场开发及商业化 艾力斯与ArriVent达成合作",
    "href": "http://stock.jrj.com.cn/2021/07/01092833026183.shtml",
    "datetime": "2021-07-01 09:28:45",
    "code": "688578"
  },
  {
    "title": "艾力斯(688578.SH)：与ArriVent就伏美替尼海外权益签署相关合作协议",
    "href": "http://stock.jrj.com.cn/2021/06/30180033022578.shtml",
    "datetime": "2021-06-30 18:00:46",
    "code": "688578"
  },
  {
    "title": "艾力斯(688578.SH)：354.7858万股限售股6月2日解禁",
    "href": "http://stock.jrj.com.cn/2021/05/24162232810833.shtml",
    "datetime": "2021-05-24 16:22:39",
    "code": "688578"
  },
  {
    "title": "艾力斯2020年亏损3.11亿 董事长杜锦豪薪酬150万",
    "href": "http://stock.jrj.com.cn/2021/04/29114332479001.shtml",
    "datetime": "2021-04-29 11:43:01",
    "code": "688578"
  },
  {
    "title": "艾力斯：在进入医保前 公司产品主要通过患者自费购药及部分商保报销",
    "href": "http://stock.jrj.com.cn/2021/04/15101632377762.shtml",
    "datetime": "2021-04-15 10:16:40",
    "code": "688578"
  },
  {
    "title": "艾力斯：公司拟通过对外授权的方式转让甲磺酸伏美替尼片（艾弗沙）在海外的开发及商业化权利",
    "href": "http://stock.jrj.com.cn/2021/04/15101032377714.shtml",
    "datetime": "2021-04-15 10:10:05",
    "code": "688578"
  },
  {
    "title": "艾力斯：甲磺酸伏美替尼片已经走进全国30个省市、覆盖全国700余家医院",
    "href": "http://stock.jrj.com.cn/2021/04/15100932377716.shtml",
    "datetime": "2021-04-15 10:09:25",
    "code": "688578"
  },
  {
    "title": "艾力斯：伏美替尼III期临床研究已于2019年底完成患者入组目前处于随访阶段",
    "href": "http://stock.jrj.com.cn/2021/04/15100632377690.shtml",
    "datetime": "2021-04-15 10:06:30",
    "code": "688578"
  },
  {
    "title": "圆心科技与艾力斯达成战略合作",
    "href": "http://stock.jrj.com.cn/kcb/2021/03/11093632107646.shtml",
    "datetime": "2021-03-11 09:36:59",
    "code": "688578"
  },
  {
    "title": "肺癌“神药”获批上市 艾力斯开启商业化新征程",
    "href": "http://stock.jrj.com.cn/kcb/2021/03/05020232073906.shtml",
    "datetime": "2021-03-05 02:02:18",
    "code": "688578"
  },
  {
    "title": "艾力斯(688578.SH)：甲磺酸伏美替尼片药品注册申请进入待制证阶段",
    "href": "http://stock.jrj.com.cn/2021/03/03154732063707.shtml",
    "datetime": "2021-03-03 15:47:20",
    "code": "688578"
  },
  {
    "title": "艾力斯2020年度亏损3.1亿 核心产品伏美替尼尚待获批",
    "href": "http://stock.jrj.com.cn/2021/02/25203932027742.shtml",
    "datetime": "2021-02-25 20:39:15",
    "code": "688578"
  },
  {
    "title": "艾力斯(688578.SH)业绩快报：2020年度亏损收窄 净亏损3.11亿元",
    "href": "http://stock.jrj.com.cn/2021/02/25175832026741.shtml",
    "datetime": "2021-02-25 17:58:57",
    "code": "688578"
  },
  {
    "title": "艾力斯：可以说伏美替尼已是预防治疗肺癌脑转移的最佳用药",
    "href": "http://stock.jrj.com.cn/2021/02/19171131993382.shtml",
    "datetime": "2021-02-19 17:11:11",
    "code": "688578"
  },
  {
    "title": "艾力斯：公司将会积极开展多项针对伏美替尼的注册性临床试验及研究者发起的临床试验",
    "href": "http://stock.jrj.com.cn/2021/02/19171031993322.shtml",
    "datetime": "2021-02-19 17:10:56",
    "code": "688578"
  },
  {
    "title": "艾力斯：公司引入的Octimet公司的c-MET抑制剂项目目前处于临床前研究阶段",
    "href": "http://stock.jrj.com.cn/2021/02/19171031993324.shtml",
    "datetime": "2021-02-19 17:10:55",
    "code": "688578"
  },
  {
    "title": "艾力斯：公司目前专注于肿瘤治疗领域",
    "href": "http://stock.jrj.com.cn/2021/02/19171031993325.shtml",
    "datetime": "2021-02-19 17:10:54",
    "code": "688578"
  },
  {
    "title": "核心产品待批、期间费用高，艾力斯2020年预亏超2.83亿元",
    "href": "http://stock.jrj.com.cn/2021/01/29095431807225.shtml",
    "datetime": "2021-01-29 09:54:33",
    "code": "688578"
  },
  {
    "title": "艾力斯2020年预计亏损2.83亿-3.25亿 核心产品尚未产生收入",
    "href": "http://stock.jrj.com.cn/2021/01/28224231803656.shtml",
    "datetime": "2021-01-28 22:42:25",
    "code": "688578"
  },
  {
    "title": "艾力斯(688578.SH)：甲磺酸伏美替尼片获批临床试验",
    "href": "http://stock.jrj.com.cn/2021/01/11190931671698.shtml",
    "datetime": "2021-01-11 19:09:16",
    "code": "688578"
  },
  {
    "title": "艾力斯：公司为依据科创板股票上市规则第2.1.2条第五项市值及财务指标上市的研发型上市公司",
    "href": "http://stock.jrj.com.cn/2021/01/04180631628614.shtml",
    "datetime": "2021-01-04 18:06:49",
    "code": "688578"
  },
  {
    "title": "艾力斯：第三代 EGFR-TKI 奥希替尼已被全球多个癌症诊断指南列为一线治疗的首选推荐",
    "href": "http://stock.jrj.com.cn/2021/01/04180631628615.shtml",
    "datetime": "2021-01-04 18:06:24",
    "code": "688578"
  },
  {
    "title": "艾力斯(688578.SH)拟以募集资金向江苏艾力斯借款以实施募投项目",
    "href": "http://stock.jrj.com.cn/2020/12/29184431596699.shtml",
    "datetime": "2020-12-29 18:44:01",
    "code": "688578"
  },
  {
    "title": "艾力斯(688578.SH)：拟使用最高不超16.8亿元暂时闲置募集资金进行现金管理",
    "href": "http://stock.jrj.com.cn/2020/12/14220931489517.shtml",
    "datetime": "2020-12-14 22:09:42",
    "code": "688578"
  },
  {
    "title": "南京高科(600064.SH)：参股公司艾力斯12月2日正式登陆科创板",
    "href": "http://stock.jrj.com.cn/2020/12/01161131385259.shtml",
    "datetime": "2020-12-01 16:11:00",
    "code": "688578"
  },
  {
    "title": "艾力斯(688578.SH)：公司股票将于12月2日起上市交易",
    "href": "http://stock.jrj.com.cn/2020/11/30191231377672.shtml",
    "datetime": "2020-11-30 19:12:55",
    "code": "688578"
  },
  {
    "title": "科创板艾力斯网上申购中签号出炉 共43200个",
    "href": "http://stock.jrj.com.cn/ipo/2020/11/22191631331568.shtml",
    "datetime": "2020-11-22 19:16:36",
    "code": "688578"
  },
  {
    "title": "今日新股申购：海融科技、协和电子、健之佳、艾力斯",
    "href": "http://stock.jrj.com.cn/2020/11/19085131313345.shtml",
    "datetime": "2020-11-19 08:51:00",
    "code": "688578"
  },
  {
    "title": "艾力斯(688578.SH)首次公开发行9000万股 发行价22.73元/股",
    "href": "http://stock.jrj.com.cn/2020/11/17191631301458.shtml",
    "datetime": "2020-11-17 19:16:23",
    "code": "688578"
  },
  {
    "title": "艾力斯(688578.SH)：网上路演时间11月18日14:00-17:00",
    "href": "http://stock.jrj.com.cn/2020/11/16190531293612.shtml",
    "datetime": "2020-11-16 19:05:28",
    "code": "688578"
  },
  {
    "title": "证监会同意艾力斯、杭华股份2家企业科创板IPO注册",
    "href": "http://stock.jrj.com.cn/2020/11/03204631210339.shtml",
    "datetime": "2020-11-03 20:46:00",
    "code": "688578"
  },
  {
    "title": "三年累计亏损超5亿元 艾力斯医药以第五套标准冲刺科创板IPO | 产业新股",
    "href": "http://stock.jrj.com.cn/2020/09/15113530754017.shtml",
    "datetime": "2020-09-15 11:35:23",
    "code": "688578"
  },
  {
    "title": "艾力斯过会:今年科创板过会第102家 中信证券过13.5单",
    "href": "http://stock.jrj.com.cn/2020/08/27100730602216.shtml",
    "datetime": "2020-08-27 10:07:00",
    "code": "688578"
  },
  {
    "title": "科创板上市委:杭华股份、艾力斯首发获通过",
    "href": "http://stock.jrj.com.cn/kcb/2020/08/26205830596223.shtml",
    "datetime": "2020-08-26 20:58:31",
    "code": "688578"
  },
  {
    "title": "16年推出两个重磅新药 艾力斯冲击科创板",
    "href": "http://stock.jrj.com.cn/kcb/2020/08/17035830510544.shtml",
    "datetime": "2020-08-17 03:58:06",
    "code": "688578"
  }
]